Axsome Therapeutics (AXSM) Net Margin (2022 - 2026)

Axsome Therapeutics has disclosed Net Margin across 5 years of filings, most recently posting 33.76% for Q1 2026.

• Net Margin for Q1 2026 came in at 33.76%, up 1516.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 26.59% (up 6207.0% YoY), and the FY2025 annual result was 28.69%, up 4577.0% from the prior year.
• Net Margin came in at 33.76% for Q1 2026 at Axsome Therapeutics, down from 14.59% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 11.88% in Q1 2023 to a low of 14982.4% in Q4 2024.
• The 5-year median for Net Margin is 91.09% (2024), against an average of 1048.22%.
• Across the five-year window, Net Margin slumped 1484448 bps in 2024 and surged 1496781 bps in 2025, its largest moves.
• Axsome Therapeutics' Net Margin stood at 251.29% in 2022, then surged by 45 bps to 137.92% in 2023, then sank by 10763 bps to 14982.4% in 2024, then soared by 100 bps to 14.59% in 2025, then plunged by 131 bps to 33.76% in 2026.
• The last three Net Margin figures came in at 33.76% (Q1 2026), 14.59% (Q4 2025), and 27.62% (Q3 2025), per Business Quant data.